Newron Pharmaceuticals S.p.A.
8.98
EUR
+0.14
(+1.58%)
Important Dates
Newron Pharmaceuticals S.p.A.'s next confirmed earnings release is scheduled for March 16, 2027.
| Earnings Date | 3/16/2027 |
Share Statistics
As of December 31, 2025, Newron Pharmaceuticals S.p.A. has 20.01M shares outstanding.
| Shares Outstanding | 20.01M |
Financial Position
As of December 31, 2025, Newron Pharmaceuticals S.p.A. maintains a current ratio of 0.76, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.76 |
| Quick Ratio | 0.58 |
| Debt / Equity | -342.73 |
Financial Efficiency
These figures cover the twelve months ended December 31, 2025.
| Employee Count | 32.00 |
Balance Sheet
EURAs of December 31, 2025, Newron Pharmaceuticals S.p.A. holds 28.88M in cash and equivalents against 38.16M in total debt, resulting in a net debt position of 25.28M. Total book value stands at -11.13M, with working capital of -12.05M providing operational flexibility.
| Cash & Cash Equivalents | 28.88M |
| Total Debt | 38.16M |
| Net Debt | 25.28M |
| Equity (Book Value) | -11.13M |
| Book Value Per Share | -0.56 |
| Working Capital | -12.05M |